Abstract: The present disclosure pertains to a tag-free CM1 polypeptide and methods for improving homology directed repair (HDR) in a recipient cell using the same. Preferred donor template delivery vehicles include Adeno virus-associated vectors for delivering donor templates, and a preferred tag-free CM1 polypeptide called CM1tf. Isolated nucleic acids encoding tag-free CM1 polypeptides are also provided.
Type:
Application
Filed:
July 13, 2026
Publication date:
November 5, 2026
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Steve Ehren GLENN, Michael Allen Collingwood, Christopher Anthony Vakulskas
Abstract: This disclosure pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRIPSR Cas9 endonuclease system.
Type:
Application
Filed:
July 14, 2026
Publication date:
November 5, 2026
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Michael Allen Collingwood, Ashley Mae JACOBI, Garrett Richard RETTIG, Mollie Sue SCHUBERT, Mark Aaron BEHLKE, Christopher Anthony Vakulskas, Rolf TURK
Abstract: The present invention pertains to a tag-free CM1 polypeptide and methods for improving homology directed repair (HDR) in a recipient cell using the same. Preferred donor template delivery vehicles include Adeno virus-associated vectors for delivering donor templates, and a preferred tag-free CM1 polypeptide called CM1tf. Isolated nucleic acids encoding tag-free CM1 polypeptides are also provided.
Type:
Grant
Filed:
August 15, 2023
Date of Patent:
September 22, 2026
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Steve Ehren Glenn, Michael Allen Collingwood, Christopher Anthony Vakulskas
Abstract: This invention pertains to isolated mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays a lower ratio of reduced off-target editing activity to on-target editing activity for at least one target site relative to the corresponding ratio of reduced off-site editing activity to on-target editing activity of a wild-type CRISPR/Cas endonuclease system having a WT-Cas9 protein of SEQ ID NO:5.
Type:
Grant
Filed:
January 20, 2024
Date of Patent:
September 1, 2026
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
Abstract: The disclosure relates to methods and compositions that serve to reduce the potential for targeted nuclease activity for example, but not limited to, CRISPR enzymes such as Cas9 and/or Cas12a. The disclosure also relates to methods and compositions be used as an HDR substrate to prevent Cas9 re-cleavage, and as a result increase the frequency of perfect HDR.
Type:
Grant
Filed:
August 18, 2021
Date of Patent:
June 16, 2026
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Garrett R. Rettig, Nathan Delvaux, Ashley M. Jacobi, Mollie S Schubert, Nathanial Roberts, Mark A Behlke
Abstract: A CRISPR-Cas-Geminin system that maintains potent on-target editing activity but has reduced off-target editing activity relative to wild-type Cas, and methods of use.
Type:
Application
Filed:
November 24, 2025
Publication date:
May 28, 2026
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Vaughn THADA, Karthik MURUGAN, Garrett R. RETTIG
Abstract: This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.
Type:
Grant
Filed:
September 8, 2021
Date of Patent:
May 5, 2026
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Mark Aaron Behlke, Michael Allen Collingwood, Rolf Turk, Christopher Anthony Vakulskas
Abstract: This invention pertains to Cas9-NLS fusion proteins and nucleic acids encoding Cas9-NLS fusion proteins for use in CRISPR/Cas endonuclease systems, and their methods of use.
Type:
Application
Filed:
February 6, 2025
Publication date:
April 16, 2026
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Christopher Anthony VAKULSKAS, Michael Allen COLLINGWOOD
Abstract: This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.
Type:
Application
Filed:
December 8, 2025
Publication date:
April 9, 2026
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Mark Aaron BEHLKE, Michael Allen COLLINGWOOD, Rolf TURK, Christopher Anthony VAKULSKAS
Abstract: Described herein are methods and compositions for improved polymerase chain reaction (PCR). In one aspect the methods and compositions include improved aptamers to reversibly inhibit polymerase and exonuclease activity of the polymerase enzyme.
Type:
Grant
Filed:
November 21, 2022
Date of Patent:
March 17, 2026
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Susan Marie Rupp, Shambhavi Shubham, Scott Rose, Brianna Cagle
Abstract: The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates.
Type:
Grant
Filed:
January 18, 2022
Date of Patent:
February 24, 2026
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Sarah Franz Beaudoin, Christopher Anthony Vakulskas
Abstract: Functionalized solid supports are useful in the synthesis of oligonucleotides. The functionalized solid supports contain an extended linker to a terminal functional group or a first nucleotide or nucleoside moiety. The extended linker permits oligonucleotide synthesis to take place at a greater distance from the solid support with greater efficiency.
Type:
Grant
Filed:
February 24, 2021
Date of Patent:
November 4, 2025
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
An Ji, Michael Marvin, Kevin Marks, David Anderson
Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.
Type:
Grant
Filed:
July 26, 2022
Date of Patent:
October 28, 2025
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Liyang Zhang, Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Kristin Renee Beltz, Mark Aaron Behlke
Abstract: The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates.
Type:
Grant
Filed:
July 20, 2021
Date of Patent:
October 7, 2025
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Sarah Franz Beaudoin, Christopher Anthony Vakulskas
Abstract: Described herein are CAS12A mutants from Lachnospiraceae bacterium and methods for use thereof. These mutants have enhanced DNA cleavage activities at non-canonical TTTT protospacer adjacent motifs (PAM) compared to the wild-type enzyme.
Type:
Grant
Filed:
February 28, 2024
Date of Patent:
October 7, 2025
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Liyang Zhang, Christopher Anthony Vakulskas
Abstract: Disclosed are DNA aptamers. Related compositions and kits are also provided. Also disclosed are methods for amplifying a target DNA sequence using the DNA aptamers, and methods of identifying the DNA aptamers.
Type:
Application
Filed:
March 28, 2025
Publication date:
October 2, 2025
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Tanner Holden Reeb, Sarah Franz Beaudoin, Christopher Anthony Vakulskas
Abstract: The present invention pertains to isolated variants of the Cas9 protein that, when complexed with a guide RNA with a scaffold sequence shorter than 76 nucleotides to form a CRISPR/Cas9 endonuclease, the resultant CRISPR/Cas9 endonuclease cleaves a double-stranded DNA target in living cells with greater efficiency than a CRISPR/Cas9 endonuclease comprising the wild-type Cas9 protein complexed with the guide RNA with a scaffold sequence shorter than 76 nucleotides.
Type:
Application
Filed:
March 20, 2025
Publication date:
September 25, 2025
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Steve Ehren GLENN, Christopher Anthony VAKULSKAS
Abstract: A bottleneck in the Next Generation Sequencing (NGS) workflow is the quantification of libraries for accurate pooling and loading of the sequencing instrument flow cell or chip. Disclosed herein are methods that improve performance and reduce time compared to existing methods.
Abstract: The present disclosure pertains to compositions, methods, and kits for improving the rate of double-strand break (DSB) repair by homology directed repair (HDR) through inhibition of 53BP1 mediated DNA end protection in combination with inhibition of microhomology-mediated end joining (MMEJ), or alternatively in combination with inhibition of non-homologous end joining (NHEJ), or in combination with inhibition of both MMEJ and NHEJ.
Type:
Application
Filed:
January 22, 2025
Publication date:
July 24, 2025
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Steve Ehren GLENN, Vaughn THADA, Christopher Anthony VAKULSKAS